Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

the completion of the Phase 1 clinical trials for AT2220 for the treatment of Pompe disease, the start of Phase 2 studies for AT2220 and the possibility and timing of conducting clinical trials of AT2220 and ERT combination therapy; (ii) statements regarding the timing and goals of discussions with US and EU regulatory authorities on the Phase 3 study and regulatory pathway for Amigal; (iii) statements on the goals, progress and timing of preclinical studies in Parkinson's disease and other research efforts aimed at evaluating disease targets in neurodegenerative and metabolic disorders; (iv) statements on the range of "cash burn" for Amicus in 2008, the need to raise additional capital in 2008 and the trends for incurring research and development expense in 2008; and (v) statements regarding expected milestone and research reimbursement payments from Shire. These forward looking statements are based on the current estimates and assumptions of the management of Amicus as of the date of this press release and the conference call and are subject to risks, changes in circumstances, assumptions and uncertainties and other factors that may cause the actual results of Amicus to be materially different from those reflected in the forward looking statements. Important factors that may cause actual results to differ materially from those indicated by forward looking statements include, among others, the potential that results of clinical or preclinical studies indicate that product candidates are unsafe or ineffective, our dependence on third parties in the conduct of our clinical studies, delays or failure to achieve regulatory approvals, risks of relying on third party manufacturers for the supply of our product candidates, we or our licensors may not be able to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of our product candidates and risks of collaborating with third parties to develop and commercialize products. Th
'/>"/>
SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... flooding that devastated a wide swath of Colorado last ... roads and other infrastructure had been upgraded or modernized, ... Colorado Denver. , "People need to understand the importance ... professor of structural engineering at the CU Denver College ... study. "There is an assumption that a bridge will ...
(Date:10/27/2014)... , October 27, 2014 ... to produce, exhibit and sell its artificial "lower ... impeach their patent.      (Photo: ... years of fighting, the definitive judgement has arrived: ... produces innovative and accessible hi-tech prostheses with composite ...
(Date:10/27/2014)... The “Molecular Diagnostic Market ... (PCR, INAAT, DNA Sequencing), End User (Hospital, Laboratories), ... Global Forecast to 2018” provides a detailed overview ... market trends, and strategies impacting the global molecular ... of the revenue and share analysis. , The ...
(Date:10/27/2014)... The report “Smart Highway Market by ... Monitoring), and by Display (Variable Message Signs, Digital ... global market into various sub-segments with in-depth analysis ... drivers and restraints for this market with insights ... market tables and 37 figures spread through 141 ...
Breaking Biology Technology:CU Denver study says upgrading infrastructure could reduce flood damage 2Italian Lower Limb Prosthesis Company Wins Lawsuit Against German Giant Ottobock 2Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 2Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 3Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 4Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 5Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 2Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 3Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 4
... , GUNMA, Japan and ATLANTA , May 17 ... Electric Corporation came to fruition in March when Gunma University Heavy Ion ... cancer. Elekta and Mitsubishi Electric worked to facilitate the use of Elekta,s ... beam treatment system. , , ...
... Latest Biomedical Licensing Opportunities , ... KANSAS CITY, Mo. , May 17 ... Innovation Network, Inc., today announced that it is continuing its strategic ... (UHN), a group of leading research hospitals and institutes based in ...
... YORK , May 17 /PRNewswire-Asia/ -- Tiens Biotech Group ( USA ), Inc. (the,"Company" or ... ended March 31, 2010 . , , , ... quarter of 2010 was $11.4 million , compared to $18.2,million for the first quarter ... Net income for the first quarter of 2010 ...
Cached Biology Technology:Elekta / Mitsubishi Electric Collaboration Helps Japan's Gunma University Heavy Ion Medical Center Launch Advanced Carbon Ion Therapy for Treating Cancer 2The iBridge Network Adds Toronto's University Health Network as First Canadian Partner 2The iBridge Network Adds Toronto's University Health Network as First Canadian Partner 3Tiens Biotech Group (USA) Reports First Quarter Results 2Tiens Biotech Group (USA) Reports First Quarter Results 3Tiens Biotech Group (USA) Reports First Quarter Results 4Tiens Biotech Group (USA) Reports First Quarter Results 5Tiens Biotech Group (USA) Reports First Quarter Results 6Tiens Biotech Group (USA) Reports First Quarter Results 7Tiens Biotech Group (USA) Reports First Quarter Results 8Tiens Biotech Group (USA) Reports First Quarter Results 9Tiens Biotech Group (USA) Reports First Quarter Results 10Tiens Biotech Group (USA) Reports First Quarter Results 11
(Date:10/29/2014)... EAST LANSING, Mich. – As bodies decompose, their ... Deciphering the clues they provide could mean the ... murder. , Michigan State University is using a ... to help Detroit death-scene investigators examine these changing ... such as geographical location of death, gender, race, ...
(Date:10/29/2014)... reveals new research potential of the Barcode of ... in the Biodiversity Data Journal ... format and imported these into a human-readable text developed ... (PWT). Data were used to study the species distributions ... Microgastrinae subfamily. , BOLD is originally designed to support ...
(Date:10/29/2014)... a hormone released by the stomach and it stimulates ... a psychoactive substance that primarily affects brain function, but ... This knowledge, combined with findings from animal studies, led ... to stimulate alcohol craving. , Dr. Lorenzo Leggio and ... as they had anticipated, alcohol craving was increased in ...
Breaking Biology News(10 mins):MSU partners with Detroit to investigate death scenes 2Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2Ghrelin stimulates an appetite for drinking alcohol 2
... SASKATCHEWAN Canadian Light Source (CLS) staff scientist Luca Quaroni ... Surgery at the University of Saskatchewan (U of S) ... with a condition known as Barrett,s Esophagus from chemical ... esophageal cancer. The finding is published in the June, ...
... French . Toronto (June 5, 2009) - ... announce another measure to address the H1N1 flu virus. The ... focused on pandemic vaccine evaluation. The network will strengthen Canada,s ... influenza vaccine and vaccination programs. The network was created ...
... Australia have presented a Canadian-based UN coral reef specialist ... in marine research. Peter Sale, Assistant Director for ... on Water, Environment and Health, and Emeritus Professor at ... for Excellence in Indo-Pacific ichthyology at the 8th Indo-Pacific ...
Cached Biology News:University of Saskatchewan and Canadian Synchrotron researchers shed light on esophageal disease 2Government of Canada announces funding for research on the H1N1 flu virus 2Canadian-based UN coral reef expert honored at world meeting in Australia 2
G-Protein Coupled Receptor Assay, For 500 assays. SPA. Category: Drug Screening & Cellular Assays, Assays ....
EDTA, disodium salt, 1 kg. Ethylene diaminetetraacetic acid.Dihydrate. Assay: 99.0-101.0%, nuclease-free.Risks: 36, 37, 38 ; Safety Precautions: 22, 36, 37. Category: Nucleotides & Enzymes & Biochemi...
Alkaline Phosphatase Stabilizer Solution, 1 L...
DEAD (Asp-Glu-Ala-Asp) box polypeptide 5...
Biology Products: